Home Cancer Genetics and Molecular Tumor Testing ASXL1 Mutation Test: Blood Cancer, Myeloid Neoplasm, and Results

Cancer Genetics and Molecular Tumor Testing

ASXL1 Mutation Test: Blood Cancer, Myeloid Neoplasm, and Results

July 28, 2026 Modified date: July 28, 2026

Understand what an ASXL1 mutation test shows in blood and bone marrow, how results relate to myeloid neoplasms and clonal hematopoiesis, and how they affect prognosis and follow-up.

An ASXL1 mutation test looks for acquired changes in the ASXL1 gene in blood or bone marrow cells. ASXL1 variants are found in several myeloid disorders, including myelodysplastic neoplasms, chronic myelomonocytic leukemia, myeloproliferative neoplasms, and acute myeloid leukemia. They can also appear in clonal hematopoiesis, an age-related expansion of blood cells that does not by itself meet criteria for cancer.

The result is therefore not interpreted alone. A positive ASXL1 finding can support classification and prognosis when it appears with abnormal blood counts, bone marrow findings, chromosome results, and other gene mutations. In some diseases it is associated with a higher-risk course, but it does not identify one specific leukemia, predict an individual outcome with certainty, or automatically select a single approved drug. Testing is usually included in a next-generation sequencing panel. The report should be reviewed by a hematologist or hematopathologist who can distinguish cancer-associated mutations from clonal hematopoiesis and possible technical artifacts.

A positive ASXL1 result means a variant was detected, but it does not by itself prove leukemia or another myeloid cancer.
ASXL1 mutations are common in myeloid neoplasms and often contribute to risk classification, especially when combined with other molecular and chromosome findings.
ASXL1 can also be found in clonal hematopoiesis in people without a diagnosed blood cancer.
The test usually uses peripheral blood or bone marrow and requires no fasting.
Variant allele frequency helps estimate how large the mutant blood-cell clone is, but it is not the percentage chance of cancer.

What ASXL1 Does in Blood Cells
When ASXL1 Testing Is Ordered
How the Test Is Performed
How to Interpret Results
ASXL1 in Specific Myeloid Disorders
Prognosis and Treatment Planning
Clonal Hematopoiesis and Follow-Up
Limitations and Questions for the Care Team

What ASXL1 Does in Blood Cells

ASXL1 stands for additional sex combs like 1. The gene helps regulate chromatin, the combination of DNA and proteins that controls which genes are active or silent. Normal blood-forming stem cells need tightly controlled chromatin programs to renew themselves and mature into red cells, white cells, and platelets.

Most clinically important ASXL1 variants in myeloid disease are frameshift or nonsense changes that create a shortened protein. A frequently reported alteration is p.Gly646TrpfsTer12, often written as G646Wfs*12. Mutant ASXL1 can disturb epigenetic regulation and cooperate with other mutations to promote abnormal stem-cell growth. It usually acts as one part of a multistep process rather than as the only cause of disease.

ASXL1 changes are generally somatic, meaning they develop in a blood stem cell during life. They are not usually inherited and do not imply that children or siblings need predictive testing. Rare germline ASXL1 variants cause Bohring-Opitz syndrome, a severe developmental condition that is clinically distinct from an adult somatic myeloid mutation. A standard blood-cancer panel is designed to detect acquired variants, not diagnose that inherited syndrome.

An ASXL1-mutated clone can range from a small population of otherwise normal blood cells to most of the cells in a myeloid cancer. The same mutation may appear in clonal hematopoiesis, myelodysplastic neoplasms, chronic myelomonocytic leukemia, primary myelofibrosis, or acute myeloid leukemia. That overlap explains why the laboratory result must be paired with the complete blood count, blood smear, bone marrow morphology, flow cytometry, cytogenetics, and clinical history.

ASXL1 often occurs with mutations in genes such as TET2, SRSF2, RUNX1, EZH2, NRAS, KRAS, JAK2, or SETBP1. The combination can be more informative than ASXL1 alone. A myeloid NGS panel can evaluate these cooperating genes in one assay, although panel content and sensitivity vary by laboratory.

When ASXL1 Testing Is Ordered

A clinician may order ASXL1 testing when blood counts, symptoms, or marrow findings suggest a myeloid neoplasm. It is rarely ordered as a stand-alone test. Instead, it is part of a panel used to classify disease, estimate risk, and establish a molecular baseline.

Common reasons include:

Persistent unexplained anemia, neutropenia, thrombocytopenia, or combinations of low counts
Persistent monocytosis suggesting chronic myelomonocytic leukemia
High platelets, high red-cell mass, splenomegaly, or marrow fibrosis suggesting a myeloproliferative neoplasm
Circulating immature myeloid cells or blasts
Suspected or newly diagnosed acute myeloid leukemia
Myelodysplastic features on a blood smear or bone marrow biopsy
Progression of a known myeloid disorder
Evaluation after treatment when a molecular marker may help track the clone

The test is not suitable as general cancer screening in healthy people. ASXL1 variants become more common with age, so testing people without a clinical reason can uncover clonal hematopoiesis that may cause anxiety and lead to unnecessary procedures. Molecular testing should answer a defined clinical question.

In acute myeloid leukemia, rapid molecular testing is important because several genetic findings influence classification, prognosis, and initial therapy. ASXL1 is one of the genes associated with myelodysplasia-related biology in modern classification systems. However, the final diagnosis still depends on blast percentage, defining genetic abnormalities, prior disease, cytogenetics, and other mutations.

In suspected myelodysplastic neoplasms, mutations can support clonality when morphology is subtle, but no single ASXL1 result replaces marrow examination. In myeloproliferative neoplasms, the main driver genes are usually JAK2, CALR, and MPL. ASXL1 is considered an additional mutation that may refine risk, especially in myelofibrosis.

Testing can also be ordered after an incidental mutation appears on broad sequencing performed for another cancer. Because white blood cells contribute DNA to blood-based assays, an ASXL1 variant found in plasma may come from clonal hematopoiesis rather than a solid tumor. Comparing matched white-cell DNA, tumor tissue, and the clinical context can prevent a false assumption that ASXL1 is a tumor target.

How the Test Is Performed

The specimen is usually peripheral blood or bone marrow aspirate. Blood may be sufficient when abnormal cells circulate, while bone marrow provides direct assessment of the disease site and allows morphology, flow cytometry, chromosome analysis, and molecular testing from the same procedure. No fasting is needed for the molecular test. Preparation for a marrow biopsy may include reviewing blood thinners, allergies, sedation plans, and local instructions.

Most laboratories use targeted next-generation sequencing. DNA is extracted, selected regions of ASXL1 and other genes are amplified or captured, and thousands of sequence reads are compared with a reference. The assay reports variants that meet quality, coverage, and allele-frequency thresholds. Some variants are confirmed by another method.

A report commonly includes:

Gene and variant notation at the DNA and protein levels
Variant type, such as frameshift, nonsense, missense, or splice-site
Variant allele frequency, often abbreviated VAF
Classification or tier based on clinical significance
Assay sensitivity and coverage limitations
An interpretive comment linking the finding to recognized diseases or guidelines

VAF is the proportion of sequence reads carrying the variant. A VAF near 40% does not mean that 40% of the body is cancer or that cancer risk is 40%. In a relatively pure diploid sample, it may suggest that a large fraction of cells carries one altered copy, but copy-number changes, sample purity, normal-cell contamination, and clonal complexity can alter the number.

Low-level variants may be clinically meaningful, but they are also more vulnerable to artifacts. The ASXL1 G646Wfs*12 region has historically been challenging because it lies near a repeated guanine sequence. Modern validated assays can detect it reliably, but laboratories should apply quality controls and confirm borderline findings when necessary.

Turnaround is commonly one to three weeks, although urgent AML panels may be faster. A negative result should be interpreted in light of the assay’s limit of detection. A clone below the threshold may be missed, and panels do not cover every possible regulatory or structural alteration.

A bone marrow biopsy supplies information that sequencing cannot: cellularity, dysplasia, fibrosis, blast count, and tissue architecture. Molecular findings complement these observations rather than replacing them.

How to Interpret Results

Pathogenic or clinically significant ASXL1 variant

A detected pathogenic or clinically significant variant shows that a blood-cell clone contains an ASXL1 alteration associated with myeloid biology. The result may support clonality, contribute to a diagnostic category, or modify prognostic scoring. It does not establish which myeloid disease is present.

The clinician asks several questions:

Are blood counts abnormal and persistent?
Does the marrow show dysplasia, fibrosis, excess blasts, or another defining pattern?
Are there chromosome abnormalities?
Which other gene mutations are present?
Is the variant level stable, rising, or falling over time?
Has the person received chemotherapy or radiation that could shape clonal hematopoiesis?

A positive result in a person with AML has different meaning from the same result in someone with normal counts. Context changes interpretation.

No ASXL1 variant detected

A negative result means no reportable ASXL1 alteration was found above the assay threshold. It does not exclude a myeloid neoplasm. Many patients with MDS, MPN, CMML, or AML do not have ASXL1 mutations, and diagnosis can rest on other genes, chromosomes, or morphology.

A negative result also does not prove that an earlier ASXL1 clone is gone unless the follow-up assay is sufficiently sensitive and the same variant was specifically assessed. Standard diagnostic NGS may detect variants down to several percent VAF, while measurable residual disease assays can be much more sensitive.

Variant of uncertain significance

A VUS is a change without enough evidence for clinical classification. It should not be treated as equivalent to a pathogenic mutation. In somatic cancer testing, laboratories may use tier systems rather than the five-category germline framework. The report should state whether the variant has established diagnostic, prognostic, or therapeutic relevance.

Possible germline finding

Most ASXL1 findings in adult hematology are acquired. However, a VAF near 50% that remains stable during remission, an unusual variant, or a relevant personal history may prompt consideration of germline testing. Blood and saliva can both contain hematopoietic cells, so cultured skin fibroblasts or another non-blood tissue may be needed. This decision belongs with a hereditary hematologic malignancy specialist.

ASXL1 in Specific Myeloid Disorders

**How ASXL1 may contribute in different clinical settings**

Setting	Role of the result	What it cannot do alone
Clonal hematopoiesis	Confirms an acquired clone when no myeloid cancer criteria are met	Predict whether or when cancer will develop
Myelodysplastic neoplasm	Supports clonality and may add adverse prognostic information	Replace marrow morphology or define MDS by itself
Chronic myelomonocytic leukemia	Common cooperating mutation and part of some molecular risk models	Distinguish reactive monocytosis without other evidence
Myelofibrosis	May be included among higher-molecular-risk mutations	Replace JAK2, CALR, MPL testing or marrow criteria
Acute myeloid leukemia	Can contribute to myelodysplasia-related classification and ELN risk	Determine treatment or transplant eligibility alone

In MDS, ASXL1 is associated in many studies with shorter survival and a higher chance of progression, but its effect depends on the full molecular profile and established scoring systems. Newer tools such as the Molecular International Prognostic Scoring System combine mutation data with counts, blasts, and cytogenetics.

In CMML, ASXL1—especially truncating variants—has been incorporated into several prognostic models. Co-mutations such as TET2 and SRSF2, white-cell count, anemia, platelets, blasts, and cytogenetics also matter. An ASXL1 result should never be reported to a patient as a complete prognosis without those variables.

In primary myelofibrosis, ASXL1 has long been considered a higher-risk mutation, although recent work suggests that the effect varies by mutation combination and model. CALR subtype, cytogenetics, age, symptoms, anemia, blasts, and other high-risk genes influence transplant discussions.

In AML, the 2022 European LeukemiaNet framework classifies AML with certain myelodysplasia-related gene mutations, including ASXL1, as adverse risk in intensively treated patients unless a favorable-risk defining abnormality takes precedence under the applicable rules. This is a population-based risk category, not a prediction of inevitable treatment failure. Measurable residual disease response can refine risk after therapy begins.

Prognosis and Treatment Planning

ASXL1 is mainly a diagnostic and prognostic biomarker rather than a directly targetable mutation with an approved ASXL1-specific drug. A positive result may influence the intensity of follow-up, the choice of prognostic model, referral for transplant evaluation, or clinical-trial consideration. It does not automatically mandate chemotherapy or stem-cell transplantation.

Treatment depends on the diagnosed disease. Low-risk clonal cytopenia may be observed. MDS treatment can range from supportive care and growth factors to hypomethylating agents, targeted drugs for other alterations, or transplant. CMML management depends on proliferative features, symptoms, blasts, and risk. Myelofibrosis options include symptom-directed therapy, JAK inhibitors, anemia treatment, clinical trials, and transplant. AML usually requires prompt therapy tailored to age, fitness, genetics, and treatment goals.

ASXL1 status may be one reason a team considers allogeneic stem-cell transplantation for an eligible person with higher-risk disease. Transplant decisions also depend on remission status, comorbidities, donor availability, estimated nonrelapse mortality, patient preferences, and the effectiveness of nontransplant options.

A baseline mutation can sometimes be followed after treatment, but ASXL1 is an imperfect measurable residual disease marker. Because ASXL1 can persist in preleukemic or clonal hematopoietic cells even when leukemia is in remission, continued detection does not always mean active AML. Conversely, disappearance on a routine panel may reflect limited assay sensitivity. More leukemia-specific markers, flow cytometry, and sensitive molecular assays may provide better residual disease information.

The value of serial testing is greatest when the same laboratory method and specimen type are used, allowing approximate comparison. Small VAF changes near the limit of detection should not be overinterpreted. A trend must be integrated with counts, marrow findings, and treatment timing.

Clonal Hematopoiesis and Follow-Up

Clonal hematopoiesis means that one blood stem-cell clone has acquired mutations and expanded. When a cancer-associated mutation is present at a VAF of at least about 2%, blood counts are normal, and no hematologic malignancy is diagnosed, the term clonal hematopoiesis of indeterminate potential, or CHIP, may apply. Smaller clones can also be detected with sensitive testing.

When persistent unexplained low blood counts accompany a myeloid-associated mutation but marrow criteria for a neoplasm are not met, clinicians may use the term clonal cytopenia of undetermined significance, or CCUS. CCUS generally carries a higher progression risk than CHIP, particularly with multiple mutations, larger clones, spliceosome mutations, or adverse mutation patterns.

An ASXL1 mutation in CHIP or CCUS does not mean leukemia is present. Follow-up may include periodic complete blood counts, review of symptoms, and reassessment if counts worsen. Bone marrow examination is not automatically repeated on a fixed schedule for every person; the plan depends on clone size, co-mutations, cytopenias, age, exposures, and trend.

Clonal hematopoiesis is also associated with cardiovascular risk in population studies. That does not mean the mutation directly causes a heart attack in an individual. Clinicians generally focus on controlling standard risk factors such as smoking, blood pressure, cholesterol, diabetes, weight, and physical activity rather than using unproven mutation-specific treatment.

Symptoms that should prompt earlier review include increasing fatigue, recurrent infections, easy bruising, bleeding, unexplained fever, night sweats, weight loss, or abdominal fullness from an enlarged spleen. Many of these symptoms have noncancer causes, but changes in combination with abnormal counts deserve evaluation.

Limitations and Questions for the Care Team

ASXL1 testing has several limitations. Panel sensitivity varies. Blood may not reflect a marrow-confined clone. Recent transfusion generally does not replace the recipient’s white-cell DNA, but transplant, donor chimerism, or severe low counts can complicate interpretation. Variant classification evolves, and the same report language may carry different significance across diseases.

The mutation can be present in a founding clone that survives treatment without representing active cancer. It can also be absent in a subclone that drives relapse. For these reasons, ASXL1 is rarely the only marker used for diagnosis or monitoring.

Useful questions include:

What diagnosis does the ASXL1 finding support in my case?
What was the VAF, and was the sample blood or marrow?
Which other mutations and chromosome changes were found?
Is this considered clonal hematopoiesis, CCUS, MDS, MPN, CMML, or AML?
Does ASXL1 change my formal risk score?
Is the finding useful for treatment monitoring, or could it persist in remission?
Should germline testing be considered?
How often should blood counts or marrow studies be repeated?
Would a clinical trial or transplant consultation be appropriate?

Urgent medical care is appropriate for uncontrolled bleeding, severe shortness of breath, chest pain, fainting, high fever with neutropenia, confusion, or rapidly worsening weakness. Test results should be discussed promptly, but an isolated ASXL1 mutation without symptoms is not by itself an emergency.

Reading changes over time

Serial ASXL1 results are easiest to understand when the original variant is named exactly and each later report uses a comparable assay. A drop from a high VAF to a low VAF after treatment may show that the clone has contracted, but the clinical meaning depends on the disease and the depth of testing. Routine NGS is not interchangeable with a highly sensitive residual-disease assay. A report that says “not detected” at a 2% limit of detection cannot exclude one mutant cell among a thousand or ten thousand.

The timing of sampling also matters. Blood collected shortly after chemotherapy may contain very few cells and may not represent the recovering marrow. Growth-factor support, marrow regeneration, infection, and transfusions can alter counts without changing the underlying clone. After allogeneic transplantation, donor cells can dilute or replace the recipient clone, and chimerism testing adds information that ASXL1 sequencing alone cannot provide.

Clinicians should compare molecular changes with the direction of blood counts and marrow findings. A rising ASXL1 VAF accompanied by worsening anemia and increasing blasts is more concerning than a small numerical fluctuation in a stable person. Conversely, stable low-level ASXL1 after successful AML therapy may represent persistent clonal hematopoiesis rather than imminent relapse. When results conflict, repeating the study, using a more sensitive method, or tracking a leukemia-defining mutation may be more informative than reacting to one isolated value.

References

Disclaimer

This information is educational and does not replace evaluation by a hematologist or hematopathologist. ASXL1 results must be interpreted with blood counts, marrow findings, cytogenetics, co-mutations, treatment history, and the assay’s sensitivity. Seek urgent care for severe bleeding, breathing difficulty, chest pain, confusion, or fever during significant neutropenia.